Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.55 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.55 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 16/20 | 0.51 |
| ▸ | P2RX2 | Q9UBL9 | 16/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2138961 | 1.00 | CACNA1I (0.55) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2140781 | 0.85 | CACNA1I (0.64) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2138097 | 0.85 | CACNA1I (0.64) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2138086 | 0.85 | CACNA1I (0.64) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2135633 | 0.83 | CACNA1I (0.62) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2135644 | 0.83 | CACNA1I (0.62) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL3062134 | 0.83 | CACNA1I (0.70) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2136815 | 0.81 | CACNA1I (0.60) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2137322 | 0.81 | CACNA1I (0.75) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2139813 | 0.81 | CACNA1I (0.60) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632899-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RaQualia Pharma Inc. (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | CACNA1I 1/4885CACNA1G 2/4885CACNA1H 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.